NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Hi meirluc.
Out of posts yesterday.
I see Ex has already responded.

Yes, as JJ clarified for me some way back, median OS is calculated, as if every patient joined the trial on the same day.
But as long as you stay alive, you cannot contribute to the calculation, unlike milestone survival (OS24, OS36 etc).

But it is still a bit surprising it hasn't moved at all.

So although long term survival is clearly better for the last 108 (or 2015 entrants) that extra benefit is all in the long tail.
Clearly, in proportional terms, more of the later contingent got to 3yr survival and beyond, than did those previously.
It's why the median OS is just a poor metric, if you want to fully demonstrate the long term survival benefit of the 25-30% who make up the long tail.
And it's why, when revamping the SAP, they are almost bound to include milestone survival in their OS analysis, and very probably RMST, which measures aggregated mean survival (not median).

Regards.